DDW: Duodenal Mucosal Resurfacing Prevents Weight Regain After Tirzepatide Withdrawal

Follow Drugslib on

By Lori Solomon HealthDay Reporter

Medically reviewed by Carmen Pope, Senior Medical Editor, B. Pharm. Last updated on April 28, 2026.

via HealthDay

TUESDAY, April 28, 2026 -- Duodenal mucosal resurfacing (DMR), an investigational endoscopic procedure, may offer a safe, effective, and lasting way to maintain drug-free weight loss following glucagon-like peptide-1 receptor agonist discontinuation, according to a study presented at Digestive Disease Week 2026, held from May 2 to 5 in Chicago.

Shelby Sullivan, M.D., from the Dartmouth Geisel School of Medicine in Hanover, New Hampshire, and colleagues report the first randomized, sham-controlled safety and efficacy outcomes from the REMAIN-1 Midpoint cohort. The analysis included 45 adults with obesity who achieved ≥15 percent total body weight loss (TBWL) with tirzepatide and were randomly assigned to resurfacing (29 people) or a sham procedure (16 people) at least one week after tirzepatide withdrawal, with six-month follow-up data.

The researchers found no device- or procedure-related serious adverse events were reported. At three months, DMR led to an additional weight loss of 2.1 kg, whereas the sham arm participants experienced an 8.2-kg regain (treatment difference, 10.3 kg). This yielded a 2.5 percent TBWL in the DMR arm versus a 10.0 percent regain in the sham arm (treatment difference, 12.5 percent). At six months, those in the sham group regained 40 percent more weight than the treatment group, with the difference between the treatment and control groups widening from one to six months postintervention, suggesting the potential for durable weight maintenance.

"Finding a treatment that allows patients to stop these medications without weight regain or loss of metabolic benefit is a huge unmet need," Sullivan said in a statement. "These findings indicate that this minimally invasive procedure may provide lasting weight-loss maintenance."

Press Release

More Information

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

Source: HealthDay

Posted : 2026-04-29 09:34

Read more

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords